Hasegawa, Hirotaka
Shitara, Kohei
Takiguchi, Shuji
Takiguchi, Noriaki
Ito, Seiji
Kochi, Mitsugu
Horinouchi, Hidehito
Kinoshita, Takahiro
Yoshikawa, Takaki
Muro, Kei
Nishikawa, Hiroyoshi
Suna, Hideaki
Kodera, Yasuhiro http://orcid.org/0000-0002-6173-7474
Funding for this research was provided by:
Ono Pharmaceutical
Bristol-Myers Squibb
Article History
Received: 8 November 2021
Accepted: 9 February 2022
First Online: 7 March 2022
Declarations
:
: H. Hasegawa reports grants from Ono Pharma, grants from Bristol Myers Squibb, during the conduct of the study. KS reports grants and personal fees from Ono Pharma, grants and personal fees from Bristol Myers Squibb, during the conduct of the study; grants and personal fees from Astellas, grants and personal fees from Eli Lilly, grants from Sumitomo Dainippon, grants from Daiichi Sankyo, grants and personal fees from Taiho Pharmaceutical, grants from Chugai Pharmaceutical, grants and personal fees from MSD, grants from Medi Science, personal fees from Takeda Pharmaceutical, personal fees from Pfizer, personal fees from Novartis, personal fees from Abbvie, personal fees from GSK, personal fees from Yakult, outside the submitted work. ST reports grants from Ono Pharma, grants from Bristol Myers Squibb, during the conduct of the study. NT reports grants from Ono Pharma, grants from Bristol Myers Squibb, during the conduct of the study. SI reports grants from Ono Pharma, grants from Bristol Myers Squibb, during the conduct of the study; grants from MSD, grants and personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, outside the submitted work. MK reports grants from Ono Pharma, grants from Bristol Myers Squibb, during the conduct of the study. H Horinouchi reports grants from Ono Pharma, grants and personal fees from Bristol Myers Squibb, during the conduct of the study; grants from Taiho Pharmaceutical, grants from Merck Serono, grants and personal fees from Novartis, grants and personal fees from MSD, grants and personal fees from Chugai Pharmaceutical, grants from Genomic Health, grants from A2 Healthcare, grants from Daiichi Sankyo, grants from AbbVie, personal fees from Eli Lilly, personal fees from AstraZeneca, personal fees from Kyowa Kirin, outside the submitted work. TK reports grants and personal fees from Ono Pharma, grants and personal fees from Bristol Myers Squibb, during the conduct of the study. TY reports grants and personal fees from Ono Pharma, grants and personal fees from Bristol Myers Squibb, during the conduct of the study; grants from Eli Lilly, personal fees from Daiichi Sankyo, personal fees from MSD, personal fees from Taiho Pharmaceutical, personal fees from Terumo, personal fees from Chugai Pharmaceutical, personal fees from Miyarisan, personal fees from EA Pharmaceutical, personal fees from AstraZeneca, personal fees from Otsuka Pharmaceutical, personal fees from Johnson and Johnson, personal fees from Covidien, outside the submitted work. KM reports grants and personal fees from Ono Pharma, grants and personal fees from Bristol Myers Squibb, during the conduct of the study; grants from Solasia Pharmaceutical, grants from Merck Serono, grants from Daiichi Sankyo, grants from Parexel International, grants from Pfizer, grants from MSD, grants and personal fees from Amgen, grants and personal fees from Sanofi, grants and personal fees from Taiho Pharmaceutical, personal fees from AstraZeneca, personal fees from Chugai Pharmaceutical, personal fees from Takeda, personal fees from Eli Lilly, personal fees from Bayer, outside the submitted work. HN reports grants and personal fees from Ono Pharma, grants and personal fees from Bristol Myers Squibb, during the conduct of the study; grants and personal fees from Chugai Pharmaceutical, grants and personal fees from MSD, grants from Taiho Pharmaceutical, grants from Daiichi Sankyo, grants from Kyowa Kirin, grants from Zenyaku Kogyo, grants from Oncollys Biopharma, grants from Deviopharma, grants from Asahi-Kasei, grants from Sysmex, grants from Fijifilm, grants from SRL, grants from Astellas, grants from Sumitomo Dainippon, grants from BD Japan, outside the submitted work. HS reports other from Ono Pharma, during the conduct of the study. YK reports grants from Ono Pharma, grants from Bristol Myers Squibb, during the conduct of the study; grants from Kaken Pharma, grants from Covidien, grants from EA Pharma, grants from Novartis, grants from KCI, grants from Maruho, grants and personal fees from Daiichi Sankyo, grants from Otsuka, grants and personal fees from Tsumura, grants from Sawai, grants and personal fees from Taiho Pharma, grants and personal fees from Chugai Pharma, grants and personal fees from Eli Lilly, grants and personal fees from Johnson & Johnson, grants and personal fees from Takeda, grants and personal fees from Yakult, grants and personal fees from Otsuka, grants and personal fees from Ono Pharma, grants and personal fees from Covidien, grants and personal fees from MSD, grants from Sanofi, grants from Shionogi, grants from Nihon Kayaku, personal fees from Bristol Myers Squibb, outside the submitted work.
: All procedures followed the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions.
: Informed consent to be included in this study was obtained from all patients.